📊 RIGL Key Takeaways
Is Rigel Pharmaceuticals Inc. (RIGL) a Good Investment?
Rigel demonstrates strong 64% revenue growth and excellent balance sheet health with low leverage (0.13x D/E) and robust cash generation. However, the 5.9% gross margin is unsustainably low for a pharmaceutical company, and the 124.7% net margin combined with 0% YoY net income growth indicates significant one-time gains artificially inflating profitability rather than operational improvement.
Rigel shows strong top-line growth and solid free cash flow alongside low leverage and ample liquidity. Yet the extraordinary operating and net margins appear driven by non-recurring items, with a very low 5.9% gross margin indicating weak underlying unit economics. Sustained improvements in recurring margins and cash conversion are needed to validate durability of earnings.
Why Buy Rigel Pharmaceuticals Inc. Stock? RIGL Key Strengths
- Exceptional revenue growth of 64.1% YoY signals strong market traction
- Fortress balance sheet with 391.5M equity, minimal leverage (0.13x D/E), and excellent liquidity (2.42x current ratio)
- Strong free cash flow of 75.2M (25.6% FCF margin) despite capital intensity typical in pharma
- 64% YoY revenue growth
- Healthy free cash flow (25.6% margin) with minimal capex
- Strong liquidity (2.42x current) and low leverage (0.13x D/E)
RIGL Stock Risks: Rigel Pharmaceuticals Inc. Investment Risks
- Critically low gross margin of 5.9% is far below pharma industry norms (60-80%), suggesting pricing power issues or unfavorable contract terms
- Net income grew 0% YoY despite 64% revenue growth; the 124.7% net margin is unsustainable and likely driven by non-recurring gains rather than core business improvement
- Disconnect between operating margin (42.6%) and net margin (124.7%) indicates quality of earnings concerns and reliance on one-time items for profitability
- Earnings quality: profits inflated by one-off/non-operating items
- Very low gross margin (5.9%) suggests weak unit economics
- Revenue mix/product concentration and regulatory risks typical for biotech
Key Metrics to Watch
- Gross margin trend and product mix shift to higher-margin revenue sources
- Breakdown of non-operating gains/losses to assess sustainability of net income
- Operating cash flow stability relative to net income to validate earnings quality
- Gross margin and product vs milestone/collaboration mix
- Operating cash flow consistency vs net income
Rigel Pharmaceuticals Inc. (RIGL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 25.6% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 2.42x current ratio provides a solid financial cushion.
RIGL Profit Margin, ROE & Profitability Analysis
RIGL vs Healthcare Sector: How Rigel Pharmaceuticals Inc. Compares
How Rigel Pharmaceuticals Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Rigel Pharmaceuticals Inc. Stock Overvalued? RIGL Valuation Analysis 2026
Based on fundamental analysis, Rigel Pharmaceuticals Inc. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Rigel Pharmaceuticals Inc. Balance Sheet: RIGL Debt, Cash & Liquidity
RIGL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Rigel Pharmaceuticals Inc.'s revenue has grown significantly by 97% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.44 indicates the company is currently unprofitable.
RIGL Revenue Growth, EPS Growth & YoY Performance
RIGL Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $55.3M | $3.1M | $0.18 |
| Q2 2025 | $36.8M | -$1.0M | $-0.06 |
| Q1 2025 | $29.5M | -$8.2M | $-0.47 |
| Q3 2024 | $28.1M | $3.1M | $0.18 |
| Q2 2024 | $26.9M | -$1.0M | $-0.06 |
| Q1 2024 | $26.1M | -$8.2M | $-0.05 |
| Q3 2023 | $22.4M | -$5.7M | $-0.03 |
| Q2 2023 | $26.9M | -$6.6M | $-0.04 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Rigel Pharmaceuticals Inc. Dividends, Buybacks & Capital Allocation
RIGL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Rigel Pharmaceuticals Inc. (CIK: 0001034842)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RIGL
What is the AI rating for RIGL?
Rigel Pharmaceuticals Inc. (RIGL) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 67% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are RIGL's key strengths?
Claude: Exceptional revenue growth of 64.1% YoY signals strong market traction. Fortress balance sheet with 391.5M equity, minimal leverage (0.13x D/E), and excellent liquidity (2.42x current ratio). ChatGPT: 64% YoY revenue growth. Healthy free cash flow (25.6% margin) with minimal capex.
What are the risks of investing in RIGL?
Claude: Critically low gross margin of 5.9% is far below pharma industry norms (60-80%), suggesting pricing power issues or unfavorable contract terms. Net income grew 0% YoY despite 64% revenue growth; the 124.7% net margin is unsustainable and likely driven by non-recurring gains rather than core business improvement. ChatGPT: Earnings quality: profits inflated by one-off/non-operating items. Very low gross margin (5.9%) suggests weak unit economics.
What is RIGL's revenue and growth?
Rigel Pharmaceuticals Inc. reported revenue of $294.3M.
Does RIGL pay dividends?
Rigel Pharmaceuticals Inc. does not currently pay dividends.
Where can I find RIGL SEC filings?
Official SEC filings for Rigel Pharmaceuticals Inc. (CIK: 0001034842) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RIGL's EPS?
Rigel Pharmaceuticals Inc. has a diluted EPS of $19.48.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RIGL a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Rigel Pharmaceuticals Inc. has a HOLD rating with 67% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RIGL stock overvalued or undervalued?
Valuation metrics for RIGL: ROE of 93.8% (sector avg: 15%), net margin of 124.7% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy RIGL stock in 2026?
Our dual AI analysis gives Rigel Pharmaceuticals Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is RIGL's free cash flow?
Rigel Pharmaceuticals Inc.'s operating cash flow is $75.7M, with capital expenditures of $450.0K. FCF margin is 25.6%.
How does RIGL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 124.7% (avg: 12%), ROE 93.8% (avg: 15%), current ratio 2.42 (avg: 2).
Why is RIGL's return on equity (ROE) so high?
Rigel Pharmaceuticals Inc. has a return on equity of 93.8%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity. This is supported by a 124.7% net margin.